Interview with Philippe van der Hofstadt, Founder & CEO, B & C Group
Can you tell our readers about B&C Groups main mission and also highlight some of its most notable achievements and milestones since its founding in 1999? Earlier in my career,…
Address: Watson & Crick Hill, Rue Granbonpré 11, B-1348 Mont-Saint-Guibert,Belgium
Tel: +32 (0)10 237 444
Web: http://www.bnc-group.com/
B & C Group is a Packaging & Logistics Company solely dedicated to (Pre)Clinical Research.
Established in 1999 as a niche provider of ground transport for batched frozen specimen shipments, B & C was the first company of its kind to offer full specimen tracking and on-site data cleaning. Today we offer a unique combination of logistics services through our network.
B & C Group adds value to your clinical research logistics process by its unique approach on centralization and integration combined with experience, expertise and geographic reach.
Since January 2009, B & C Group has relocated its two sites in Mechelen and Wavre to the former Eli Lilly IMP Packaging & distribution facility in Mont-St-Guibert (South of Brussels – Belgium).
B & C provides integrated Packaging and Logistics services for the Clinical Trials sponsored or supported by:
Pharmaceutical Companies
Biotechnology Companies
Central Laboratories
Contract Research Organizations
Academic Institutions
Investigational Sites
Can you tell our readers about B&C Groups main mission and also highlight some of its most notable achievements and milestones since its founding in 1999? Earlier in my career,…
Belgium’s healthcare system was ranked fourth in Europe in 2019, outperforming its peers across a number of metrics including a relatively high number of hospital beds per capita (six per…
Carl Laurent, managing director and CEO of Siemens Healthineers BeLux, sits down with PharmaBoardroom to explain Siemens Healthineers’ footprint and impact in Belgium and Luxembourg, the importance of appreciating diagnostics…
Axel De Muyt, general manager & VP of Novo Nordisk Belgium and Luxembourg, recounts his journey through the pharma industry, how he has been able to revive the company’s perspectives…
In late 2019 Novartis hit the headlines in Belgium after it refused to grant access to its one-off gene therapy Zolgensma® for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA)…
GSK, the world’s largest manufacturer of vaccines, has pursued a different strategy to that of its contemporaries in the effort to develop a safe, effective, and mass-producible COVID-19 vaccine. PharmaBoardroom…
Alexander Alonso, general manager of medtech giant BD’s operations in Belgium, the Netherlands, and Luxembourg outlines the company’s extensive footprint in the region, how it has rapidly mobilised in the…
Philippe de Pougnadoresse, country president & general manager pharma for Novartis Belgium & Luxembourg, outlines his affiliate’s fast and comprehensive response to the COVID-19 crisis, what can be learned from…
Vincent Stephenne, managing director of Belgian CDMO BePharBel Manufacturing, highlights the company’s innovative approach to developing new galenic forms for existing molecules, its growth trajectory thus far, and his future…
Christophe Van Damme, vice president and general manager of Perrigo Belgium and Luxembourg, shines a light on the transformation for Perrigo since its acquisition of Omega Pharma in 2015. Van…
Veronique Walsh, general manager of Bristol Myers Squibb for Belgium, the Netherlands, and Luxembourg (Benelux), recently spoke to PharmaBoardroom about her diverse career path, transitioning from medical doctor to pharmaceutical…
In an exclusive interview, GSK’s Senior VP for Vaccines R&D Dr Emmanuel Hanon discusses how the sharing of GSK’s adjuvant technology with a wealth of scientific institutions and companies globally…
Veronique Walsh, General Manager of Bristol Myers Squibb (BMS) – Benelux, explains her ambition to build a new company culture following the acquisition of Celgene. Walsh also lays bare the…
See our Cookie Privacy Policy Here